3 active not recruiting, 3 completed, 2 recruiting, 1 not yet recruiting. 10 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Active not recruiting 3, Completed 3, Recruiting 2, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 6 | Active not recruiting 3, Completed 1, Recruiting 1, Unknown 1 |
Follow tipiracil: new trials by email Literature Review of tipiracil trials Research Report on tipiracil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Trifluridine/Tipiracil (TAS-102) Combined With Bevacizumab and Serplulimab in Patients With Metastatic Colorectal Cancer Undergoing Cytoreductive Surgery: A Single-Arm, Single-Center Clinical Study Trifluridine/tipiracil (TAS-102) combined with bevacizumab and ptemizumab - Colorectal Cancer (CRC) | Phase 1 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 20 | 2026-06-06 | 2026-06-08 |
| Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . nal-IRI /Experimental, Ramucirumab /Experimental, Trifluridine/Tipiracil /Experimental - Metastatic Gastric Adenocarcinoma, Second Line | Phase 1 / Phase 2 | Recruiting | National Health Research Institutes, Taiwan | 45 | 2024-04-01 | 2026-04-09 |
| Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study Fruquintinib plus immunocheckpoint inhibitor plus trifluridine/tipiracil, Fruquintinib plus immunocheckpoint inhibitor followed by trifluridine/tipiracil plus bevacizumab - Colorectal Cancer | Phase 1 / Phase 2 | Active not recruiting | Tianjin Medical University Cancer Institute and Hospital | 106 | 2023-07-01 | 2026-03-24 |
| Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®) - Gastric and Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Yonsei University | 75 | 2022-12-01 | 2025-07-11 |
| Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine trifluridine/tipiracil + XB2001, trifluridine/tipiracil + placebo - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Active not recruiting | Centre Georges Francois Leclerc | 160 | 2022-10-13 | 2025-05-30 |
| Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 70 | 2022-10-01 | 2024-04-02 |
| Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas TAS-102, Irinotecan, Standard Treatment - Colon Adenocarcinoma, Colorectal Cancer | Phase 1 | Recruiting | University of California, Irvine | 22 | 2021-08-26 | 2026-05-11 |
| TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma TAS-102, Irinotecan - Gastric Adenocarcinoma, GastroEsophageal Cancer | Phase 1 | Completed | University of California, Irvine | 20 | 2019-08-26 | 2024-02-02 |
| Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients Trifluridine and Tipiracil Tablets, TAS-102 - Colorectal Cancer | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 64 | 2019-05-21 | 2022-04-19 |
| A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer Panitumumab + TAS-102 - Colorectal Cancer | Phase 1 / Phase 2 | Completed | Takeda | 56 | 2015-12-07 | 2019-07-31 |
Colorectal Neoplasms (7) · Colonic Neoplasms (1)
University of California, Irvine (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Centre Georges Francois Leclerc (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · National Health Research Institutes, Taiwan (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Takeda (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Yonsei University (1)
China (3) · United States (2) · France (1) · Japan (1) · South Korea (1) · Taiwan (1)
Farshid Dayyani, MD, PhD (2) · Nai-Jung Chiang, MD-PhD (1) · Yongkun Sun (1)
PMID 11230497, PMID 11489791, PMID 11895891, PMID 16271446, PMID 1651156, PMID 17468871, PMID 19349540, PMID 22811849, PMID 23406728, PMID 23880820, PMID 25577133, PMID 26615328, PMID 27091418, PMID 27871319, PMID 36622402, PMID 39530624, PMID 39820336, PMID 40468090